脯氨酰羟化酶结构域抑制剂治疗慢性肾脏病贫血的新方法
贫血是慢性肾脏病常见并发症,主要因受损肾脏不能产生足够促红细胞生成素。缺氧诱导因子(HIF)调控促红细胞生成素转录,脯氨酰羟化酶结构域蛋白介导常氧下HIF-α降解,抑制该酶可增加缺氧诱导基因表达包括促红细胞生成素。脯氨酰羟化酶结构域抑制剂改善铁代谢并促进红细胞生成,至少6种小分子抑制剂已在人体测试,临床试验显示有效且未引起严重不良事件,但HIF系统性激活存在肿瘤发生和严重肺动脉高压的理论担忧,需未来临床研究仔细评估。
要点
- 脯氨酰羟化酶结构域抑制剂通过稳定HIF增加促红细胞生成素转录。
- 该类药物改善铁代谢,协同促进红细胞生成。
- 至少6种小分子抑制剂人体试验有效且无严重不良事件。
核心结论
- 脯氨酰羟化酶结构域抑制剂是治疗慢性肾脏病贫血的新兴治疗手段,人体试验显示有效且未报告严重不良事件。
- HIF系统性激活可能带来肿瘤发生和严重肺动脉高压等不良效应,需未来临床研究仔细评估。
研究设计与样本
- 综述性文章,总结脯氨酰羟化酶结构域抑制剂作为慢性肾脏病贫血新型治疗方法的机制与临床证据。
- 提及至少6种小分子脯氨酰羟化酶结构域抑制剂已在人体进行测试。
主要发现
- 抑制脯氨酰羟化酶结构域蛋白可增加缺氧诱导基因表达,包括促红细胞生成素。
- 脯氨酰羟化酶结构域抑制改善铁代谢,有助于红细胞生成。
- 临床试验显示至少6种小分子抑制剂有效且未引起严重不良事件。
临床怎么用
- 脯氨酰羟化酶结构域抑制剂可作为慢性肾脏病贫血的潜在治疗选择,但需关注HIF激活的远期安全性。
局限性
- HIF系统性激活可能诱导肿瘤发生和严重肺动脉高压,需未来临床研究仔细评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anemia is a common complication of chronic kidney disease and is mainly caused by the inability of injured kidneys to produce adequate amounts of erythropoietin. Studies elucidating the regulation of erythropoietin production led to the identification of hypoxia-inducible factor (HIF), which activates the transcription of genes that mediate adaptive responses to hypoxia. HIF is a heterodimer that consists of an α and β subunit. While HIF-β is constitutively expressed, HIF-α is subjected to ubiquitination and proteasomal degradation under normoxic conditions. This process is mediated by prolyl hydroxylase domain proteins, the inhibition of which results in an increased expression of hypoxia-induced genes, including erythropoietin. These findings led to the development of prolyl hydroxylase domain inhibitors as novel therapeutic agents against anemia in chronic kidney disease. Prolyl hydroxylase domain inhibition improves iron metabolism, which also contributes to erythropoiesis. To date, at least 6 small-molecule inhibitors of the prolyl hydroxylase domain have been tested in humans, and clinical trials have shown that they are effective without causing serious adverse events. However, there is a theoretical concern that the systemic activation of HIF could also induce deleterious effects such as tumorigenesis and severe pulmonary hypertension, which demands careful assessments in future clinical studies.
引用
- Sugahara M, Tanaka T, Nangaku M, et al. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. Kidney Int. 2017. PMID: 28651951. doi:10.1016/j.kint.2017.02.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。